TTF device market seen reaching $1.35 billion by 2030

The tumor treating fields device market is projected to grow from $0.75 billion in 2026 to $1.35 billion by 2030, driven by rising cancer cases, broader clinical use and expanding reimbursement. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Tumor treating fields devices offer a non-invasive cancer treatment option that can be used alongside chemotherapy and radiation. - The market’s growth reflects rising demand for therapies that can slow tumor growth without surgery or systemic side effects. - The market is also tied to the expanding global cancer burden, including glioblastoma and malignant mesothelioma.

What happened: - The Business Research Company published a 2026 report on the tumor treating fields device market covering market size, trends and a global forecast through 2035. - The report says the market will grow from $0.65 billion in 2025 to $0.75 billion in 2026. - The report forecasts the market will reach $1.35 billion by 2030, implying a 15.9% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company is offering a free sample of the report and a full report download through its website. Download a free sample - View the full report

The details: - Tumor treating fields devices use low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. - The devices deliver electric fields through transducer arrays placed on the skin near the tumor location. - The technology is used most often for glioblastoma and malignant pleural mesothelioma. - The 2026-to-2030 growth outlook is supported by more glioblastoma and malignant mesothelioma cases, regulatory approvals, clinical validation and early gains in progression-free survival. - Other growth drivers include transducer array design improvements, better wearable oncology devices and wider acceptance of non-invasive cancer treatments. - The longer-term forecast is supported by broader indications, including non-small cell lung cancer and pancreatic cancer. - The market is also expected to benefit from higher demand for home-based cancer therapies, more reimbursement coverage, more combination therapy use and patient demand for non-invasive oncology options. - Expected trends include expanded payer coverage, a shift toward ambulatory cancer care, biocompatible transducer arrays that reduce skin irritation, broader adoption beyond glioblastoma, and more physician education and training.

Between the lines: - The report points to a market moving from niche use toward wider oncology adoption. - Reimbursement and payer coverage may be as important as clinical progress for commercial growth. - Home-based treatment demand suggests patients and providers are looking for more convenient cancer care models. - The emphasis on biocompatible arrays shows that comfort and skin irritation remain practical barriers to broader use. - Global cancer incidence is strengthening the case for targeted therapies that can complement existing treatment regimens. - World Health Organization data cited in the report said there were about 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022. - The number of new cancer diagnoses is expected to exceed 35 million by 2050, a 77% increase from 2022.

What's next: - Market growth is expected to accelerate as TTF devices expand into more solid tumors and gain broader clinical adoption. - Expansion of reimbursement policies could help move treatment from specialized centers into more routine oncology care. - Physician education and training will likely play a larger role as the technology spreads beyond glioblastoma. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards and market hotspot graphics.